 Cytotoxicity, Immunologic
"Cytotoxicity, Immunologic" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The phenomenon of target cell destruction by immunologically active effector cells. It may be brought about directly by sensitized T-lymphocytes or by lymphoid or myeloid "killer" cells, or it may be mediated by cytotoxic antibody, cytotoxic factor released by lymphoid cells, or complement.
| Descriptor ID |
D003602
|
| MeSH Number(s) |
G12.287
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Cytotoxicity, Immunologic".
Below are MeSH descriptors whose meaning is more specific than "Cytotoxicity, Immunologic".
This graph shows the total number of publications written about "Cytotoxicity, Immunologic" by people in this website by year, and whether "Cytotoxicity, Immunologic" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 2 | 1 | 3 | | 1997 | 0 | 2 | 2 | | 1998 | 3 | 3 | 6 | | 1999 | 0 | 3 | 3 | | 2000 | 3 | 3 | 6 | | 2001 | 2 | 4 | 6 | | 2002 | 1 | 3 | 4 | | 2003 | 0 | 5 | 5 | | 2004 | 0 | 5 | 5 | | 2005 | 1 | 3 | 4 | | 2006 | 0 | 5 | 5 | | 2007 | 0 | 5 | 5 | | 2008 | 0 | 3 | 3 | | 2009 | 1 | 5 | 6 | | 2010 | 0 | 5 | 5 | | 2011 | 1 | 2 | 3 | | 2012 | 1 | 2 | 3 | | 2013 | 2 | 3 | 5 | | 2014 | 2 | 2 | 4 | | 2015 | 3 | 2 | 5 | | 2016 | 2 | 5 | 7 | | 2017 | 0 | 2 | 2 | | 2018 | 1 | 5 | 6 | | 2019 | 0 | 6 | 6 | | 2020 | 1 | 4 | 5 | | 2021 | 0 | 1 | 1 | | 2023 | 0 | 1 | 1 | | 2024 | 1 | 5 | 6 | | 2025 | 3 | 1 | 4 | | 2026 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Cytotoxicity, Immunologic" by people in Profiles.
-
Gurrea-Rubio M, Sloan S, Chada A, Amarista CI, Maeda K, Campbell PL, Tsou PS, Cooney LA, Wicha MS, Fox DA. CD6-Directed Immunotherapy Targets Breast Cancer Stem Cell Function and Enhances Immune-Mediated Cytotoxicity in Triple-Negative Breast Cancer. Biomolecules. 2026 Aug 17; 16(8).
-
Niessl J, Müller TR, Constantz C, Cai C, Nilsén V, Rivera Ballesteros O, Adamo S, Kammann T, Mouchtaridi E, Gao Y, Akhirunnesa M, Raineri EJM, Weigel W, Kokkinou E, Stamper C, Marchalot A, Bassett J, Ferreira S, Rodahl I, Wild N, Stellaccio T, Brownlie D, Ringqvist E, Flodström-Tullberg M, Llewellyn-Lacey S, Tibbitt C, Hammer Q, Michaëlsson J, Price DA, Mjösberg J, Marquardt N, Sandberg JK, Sekine T, Jorns C, Buggert M. Tissue origin and virus specificity shape human CD8+ T cell cytotoxicity. Sci Immunol. 2025 07 18; 10(109):eadq4881.
-
Kuznetsova V, Krishnan V, Costa A, Ren X, Ricketts TD, Patel SB, Connelly AN, Goel P, Knapp JP, Franceski AM, Luca F, Lobo de Figueiredo-Pontes L, Bhatia R, Prabhakar S, Ong ST, Welner RS. Chronic inflammation deters natural killer cell fitness and cytotoxicity in myeloid leukemia. Blood Adv. 2025 Feb 25; 9(4):759-773.
-
Phung SK, Zorko NA, Soignier Y, Waller RL, Shackelford M, Walker JT, Nelson TD, Selleck C, Bendzick LE, Kotz LE, Kile QM, Bozicevich AJ, Miller SE, Khaw M, Shetty M, Hinderlie P, Ehrhardt M, Li Y, Luo X, Dehm SM, Antonarakis ES, Kennedy PR, Miller JS, Felices M. A PSMA-Targeted Tri-Specific Killer Engager Enhances NK Cell Cytotoxicity against Prostate Cancer. Cancer Immunol Res. 2025 Feb 03; 13(2):258-272.
-
DeGolier KR, Danis E, D'Antonio M, Cimons J, Yarnell M, Kedl RM, Kohler ME, Scott-Browne JP, Fry TJ. Antigen experience history directs distinct functional states of CD8+ CAR T cells during the antileukemia response. Nat Immunol. 2025 01; 26(1):68-81.
-
Zhang Z, Langenbach M, Sagar S, Fetsch V, Stritzker J, Severa E, Meng K, Winkler F, Rana N, Zoldan K, Godbole I, Solis S, Weber JS, Rafei-Shamsabadi D, Lehr S, Diehl R, Venhoff AC, Voll RE, Buettner N, Neumann-Haefelin C, Boettler T, Hofmann M, Boerries M, Meiss F, Zeiser R, Thimme R, Herati RS, Bengsch B. Efficacy of CTLA-4 checkpoint therapy is dependent on IL-21 signaling to mediate cytotoxic reprogramming of PD-1+CD8+ T cells. Nat Immunol. 2025 Jan; 26(1):92-104.
-
Escoto A, Hecksel R, Parkinson C, Crane S, Atwell B, King S, Ortiz Chavez D, Jannuzi A, Sands B, Bitler BG, Fehniger TA, Paek AL, Padi M, Schroeder J. Nuclear EGFR in breast cancer suppresses NK cell recruitment and cytotoxicity. Oncogene. 2025 02; 44(5):288-295.
-
Ngiow SF, Manne S, Huang YJ, Azar T, Chen Z, Mathew D, Chen Q, Khan O, Wu JE, Alcalde V, Flowers AJ, McClain S, Baxter AE, Kurachi M, Shi J, Huang AC, Giles JR, Sharpe AH, Vignali DAA, Wherry EJ. LAG-3 sustains TOX expression and regulates the CD94/NKG2-Qa-1b axis to govern exhausted CD8 T cell NK receptor expression and cytotoxicity. Cell. 2024 Aug 08; 187(16):4336-4354.e19.
-
Wu X, Chen PI, Whitener RL, MacDougall MS, Coykendall VMN, Yan H, Kim YB, Harper W, Pathak S, Iliopoulou BP, Hestor A, Saunders DC, Spears E, Sévigny J, Maahs DM, Basina M, Sharp SA, Gloyn AL, Powers AC, Kim SK, Jensen KP, Meyer EH. CD39 delineates chimeric antigen receptor regulatory T cell subsets with distinct cytotoxic & regulatory functions against human islets. Front Immunol. 2024; 15:1415102.
-
Hay ZLZ, Kim DD, Cimons JM, Knapp JR, Kohler ME, Quansah M, Zúñiga TM, Camp FA, Fujita M, Wang XJ, O'Connor BP, Slansky JE. Granzyme F: Exhaustion Marker and Modulator of Chimeric Antigen Receptor T Cell-Mediated Cytotoxicity. J Immunol. 2024 04 15; 212(8):1381-1391.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|